Annexon Net Income From Continuing Ops Over Time
| ANNX Stock | USD 6.24 0.28 4.29% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Annexon Performance and Annexon Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annexon. If investors know Annexon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Annexon assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Annexon requires distinguishing between market price and book value, where the latter reflects Annexon's accounting equity. The concept of intrinsic value—what Annexon's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Annexon's price substantially above or below its fundamental value.
Understanding that Annexon's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Annexon represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Annexon's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Annexon and related stocks such as DBV Technologies, Larimar Therapeutics, and Altimmune Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DBVT | (19.3 M) | (19.3 M) | (19.3 M) | (19.3 M) | (24 M) | (57.2 M) | (114.5 M) | (147.7 M) | (166.1 M) | (153.6 M) | (159.6 M) | (97.8 M) | (96.3 M) | (100.8 M) | (113.9 M) | (102.5 M) | (107.7 M) |
| LRMR | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (42.5 M) | (50.6 M) | (35.4 M) | (36.9 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| ALT | (3.8 M) | (3.8 M) | (4.9 M) | (11.7 M) | (10 M) | (3.4 M) | 193.9 M | (46.4 M) | (39.2 M) | (20.5 M) | (49 M) | (97.1 M) | (84.7 M) | (88.4 M) | (95.1 M) | (85.6 M) | (81.3 M) |
| KRRO | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (58 M) | (81.2 M) | (83.6 M) | (75.2 M) | (79 M) |
| LBRX | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (6.3 M) | (63.1 M) | (56.8 M) | (54 M) |
| AURA | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (22.2 M) | (35.3 M) | (58.8 M) | (70.8 M) | (86.9 M) | (78.2 M) | (82.1 M) |
| KYTX | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (28.9 M) | (60.4 M) | (127.5 M) | (114.7 M) | (109 M) |
| ACIU | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | 10.8 M | 20.1 M | (7.1 M) | (26.4 M) | (51 M) | 45.4 M | (61.9 M) | (73 M) | (70.8 M) | (54.2 M) | (50.9 M) | (45.8 M) | (43.5 M) |
| DMAC | 0.0 | 0.0 | 0.0 | 0.0 | (4.8 M) | (1.6 M) | (2.2 M) | (4.3 M) | (5.7 M) | (10.6 M) | (12.3 M) | (13.6 M) | (13.7 M) | (18 M) | (24.4 M) | (22 M) | (20.9 M) |
Annexon and related stocks such as DBV Technologies, Larimar Therapeutics, and Altimmune Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Annexon | ANNX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1400 Sierra Point |
| Exchange | NASDAQ Exchange |
USD 6.24
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.